Literature DB >> 8594514

Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications.

D C Lundy1, P Sidoti, T Winarko, D Minckler, D K Heuer.   

Abstract

PURPOSE: To describe the authors' clinical experience with intracameral tissue plasminogen activator (tPA) after glaucoma surgery.
METHODS: Retrospective review of medical records of all patients who received intracameral tPA after glaucoma surgery at the Doheny Eye Institute from November 4, 1992, to June 14, 1994. There were 20 tPA administrations (18 eyes of 17 patients) in doses ranging from 6 to 25 microgram. Indication for tPA administration was decreased bleb function secondary to blood/fibrin clot in aqueous outflow pathway.
RESULTS: Tissue plasminogen activator was given after trabeculectomy (5 drug administrations) and combined cataract extraction/trabeculectomy procedures (9 drug administrations), with increased filtration in 12 (86%). There were five (36%) instances of hyphema and three (21%) of hypotony. All hyphemas occurred after doses of 25 microgram. Final IOP of 18 mmHg or lower and 6 mmHg or higher was achieved in 11 (92%) of 12 patients after a mean follow-up interval of 4.2+/-4.7 months. The six remaining tPA irrigations were done in five patients after glaucoma drainage implant surgery (n=4) or surgical/needle revision of a filtering bleb (n=2).
CONCLUSIONS: Aqueous outflow obstruction from blood/fibrin clot after glaucoma surgery may be treated effectively with intracameral tPA in doses of 6 to 25 microgram. The authors recommend using a dose of less than or equal to 6 to 12.5 microgram to minimize risk of hyphema.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8594514     DOI: 10.1016/s0161-6420(96)30704-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Intracameral injection of tissue plasminogen activator to treat severe postoperative fibrinous reaction in iridocorneal endothelial syndrome.

Authors:  Bryan K Hong; Brian A Francis
Journal:  Digit J Ophthalmol       Date:  2013-05-01

3.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

4.  Intracameral recombinant tissue plasminogen activator for refractory glaucoma secondary to a fungal corneal abscess.

Authors:  L Jay Katz; Oana Stirbu; Garth Willis; Parul Ichhpujani
Journal:  Open Ophthalmol J       Date:  2009-09-25

5.  Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.

Authors:  Sylves Patrick; Chan Hui-Tze; Wan Hitam Wan-Hazabbah; Embong Zunaina; Yaakub Azhany; Ahmad Tajudin Liza-Sharmini
Journal:  J Taibah Univ Med Sci       Date:  2018-04-06

6.  Nd:YAG capsulotomy for Ahmed glaucoma drainage implant occlusion by the anterior capsule: a case report.

Authors:  Monica Kenney Ertel; Nathaniel Ryan Gelinas; Taylor John Slingsby; Leonard Keith Seibold; Malik Yaser Kahook; Jeffrey Raymond SooHoo
Journal:  BMC Ophthalmol       Date:  2021-02-06       Impact factor: 2.209

7.  Towards smart self-clearing glaucoma drainage device.

Authors:  Hyunsu Park; Amir Hossein Raffiee; Simon W M John; Arezoo M Ardekani; Hyowon Lee
Journal:  Microsyst Nanoeng       Date:  2018-11-05       Impact factor: 7.127

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.